Visterra-Serum Combine Forces For Dengue Therapy
US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.
US biotech, Visterra, has joined hands with vaccine giant, Serum Institute of India, to take its early stage monoclonal antibody product candidate (VIS513) for dengue forward.